BCG Culture SSI (Danish strain 1331) is significantly superior
to mitomycin C for superficial bladder cancer in patients at high
risk for progression and recurrence of their disease.
A large Nordic randomised clinical trial demonstrated a substantially
lower recurrence rate, a longer time to treatment failure, and
fewer cystectomies for patients treated with BCG Culture SSI 6.